Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2017-01-19 |
Anavex Life Sciences (USA - NY) |
$ 0.6 million |
grant |
Rettsyndrome.org (USA - OH) |
Neurological diseases - CNS diseases |
Grant |
2017-01-19 |
Octimet Oncology (Belgium) |
€ 11.3 million |
series A financing round |
V-Bio Ventures (Belgium) Fund+ (Belgium) DROIA Oncology Ventures (Luxembourg/Belgium) OMNES Capital (France) |
Cancer - Oncology |
Series A financing round |
2017-01-19 |
PCI Biotech (Norway) |
|
capital increase |
|
Cancer - Oncology |
Capital increase |
2017-01-17 |
Fibrocor Therapeutics (Canada) |
$ 2.1 million |
financing round |
Evotec (Germany) MaRS Innovation (Canada) |
Fibrotic diseases |
Financing round |
2017-01-11 |
Mirati Therapeutics (USA - CA) |
$65 million |
private placement |
|
Cancer - Oncology |
Private placement |
2017-01-10 |
Loxo Oncology (USA - CA) |
$138 million |
private placement |
|
Cancer - Oncology |
Private placement |
2017-01-09 |
Eternygen (Germany) |
€ 8 million |
series A financing round |
Evotec (Germany) Epidarex Capital (UK) EMBL Ventures (Germany) IBB Beteiligungsgesellschaft GmbH (Germany) two renowned family offices. |
Metabolic diseases |
Series A financing round |
2017-01-09 |
Abivax (France) |
€8.4 million |
grant |
Bpifrance (France) |
Infectious diseases |
Grant |
2017-01-09 |
Kymab (UK) |
$9 million |
grant |
Bill & Melinda Gates Foundation (USA) |
Infectious diseases |
Grant |
2017-01-09 |
Y-mAbs Therapeutics (USA - NY) |
$12 million |
private placement |
|
Cancer - Oncology |
Private placement |
2017-01-06 |
PCI Biotech (Norway) Ultimovacs (Norway) |
NOK 500,000 |
grant |
Innovation Norway (Norway) |
Cancer - Oncology |
Grant |
2017-01-05 |
Therachon (France) |
$ 40 million |
series A financing round |
OrbiMed (USA - NY) New Enterprise Associates (NEA) (USA - MD) Inserm Transfert Initiative (ITI) (France) Versant Ventures (USA - CA) Bpifrance (France) |
Rare diseases - Genetic diseases |
Series A financing round |
2017-01-05 |
Nerre Therapeutics (UK) |
£23 million |
series B financing round |
Fountain Healthcare Partners (Ireland) Forbion Capital Partners (The Netherlands) OrbiMed (USA - NY) Advent Life Sciences (UK) Novo A/S (Sweden) |
|
Series B financing round |
2017-01-05 |
Neon Therapeutics (USA - MA) |
$70 million |
series B financing round |
|
Cancer - Oncology |
Series B financing round |
2017-01-04 |
Clovis Oncology (USA - CO) |
$175 million |
private placement |
|
Cancer - Oncology |
Private placement |
2016-12-21 |
Oryzon Genomics (Spain) |
$ 0.8 million |
grant |
Ministry of Economy and Competitiveness, Government of Spain, FEDER Funds |
Inflammatory diseases |
Grant |
2016-12-20 |
Tigenix (Belgium) |
$35.65 million |
IPO |
|
Autoimmune diseases - Inflammatory diseases - Digestive diseases - Regenerative medicine |
IPO |
2016-12-20 |
Phi Pharma (Switzerland) |
CHF 3.7 million |
series A financing round |
undisclosed investor |
Cancer - Oncology - Infectious diseases |
Series A financing round |
2016-12-19 |
Nabriva Therapeutics (Austria) |
$25 million |
private placement |
|
Infectious diseases |
Private placement |
2016-12-16 |
Soligenix (USA - NJ) |
$ 5.28 million |
private placement |
|
Rare diseases |
Private placement |